Showing results (221-230 of 258) with videos related to

Sort By:
Pageof 26
Archives of Gynecology and Obstetrics|February 16, 2018
Correction to: The use of PIPAC (pressurized intraperitoneal aerosol chemotherapy) in gynecological oncology: a statement by the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) Kommission Ovar, AGO Study Group, North-Eastern German Society of Gynaecologic Oncology (NOGGO), AGO Austria and AGO SwitzerlandA M Dueckelmann, D Fink, P Harter, et al.
Geburtshilfe Und Frauenheilkunde|March 5, 2016
Statement of the AGO Kommission Ovar, AGO Study Group, NOGGO, AGO Austria and AGO Switzerland Regarding the Use of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Ovarian CancerP Harter, A du Bois, S Mahner, et al.
Gene Therapy|July 26, 2002
Determination of molecules regulating gene delivery using adenoviral vectors in ovarian carcinomasA G Zeimet, E Müller-Holzner, A Schuler, et al.
Anticancer Research|February 24, 2001
Peritoneal mesothelial cells as a significant source of ascitic immunostimulatory protein 90KA G Zeimet, S Stadlmann, C Natoli, et al.
Cancer Research|November 1, 1990
Gamma-interferon reduces expression of the protooncogene c-erbB-2 in human ovarian carcinoma cellsC Marth, E Müller-Holzner, E Greiter, et al.
The American Journal of Pathology|December 14, 1999
Basic fibroblast growth factor synthesis by human peritoneal mesothelial cells: induction by interleukin-1M V Cronauer, S Stadlmann, H Klocker, et al.
Blood|August 15, 1996
Evidence for a graft-versus-tumor effect in a patient treated with marrow ablative chemotherapy and allogeneic bone marrow transplantation for breast cancerB Eibl, H Schwaighofer, D Nachbaur, et al.
International Journal of Cancer|September 17, 1996
Different effects of interferons, interleukin-1beta and tumor necrosis factor-alpha in normal (OSE) and malignant human ovarian epithelial cellsC Marth, A G Zeimet, M Herold, et al.
Gynakologisch-Geburtshilfliche Rundschau|January 1, 1992
[Interferon-gamma suppresses expression of the HER-2 oncogene in ovarian cancer cells]C Marth, E Müller-Holzner, A G Zeimet, et al.
Cancer|May 1, 1991
Formation of neutralizing antibodies against natural interferon-beta, but not against recombinant interferon-gamma during adjuvant therapy for high-risk malignant melanoma patientsR Dummer, W Müller, F Nestle, et al.
Pageof 26